| Monica Renee Chetwin, MS CCC-SLP | |
|
350 S Cedarbrook Rd, Allentown, PA 18104-5708 | |
| (315) 857-5723 | |
| Not Available |
| Full Name | Monica Renee Chetwin |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 350 S Cedarbrook Rd, Allentown, Pennsylvania |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306413067 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | SL015051 (Pennsylvania) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Monica Renee Chetwin, MS CCC-SLP 1621 Cloverleaf St, Bethlehem, PA 18017-5132 Ph: (315) 857-5723 | Monica Renee Chetwin, MS CCC-SLP 350 S Cedarbrook Rd, Allentown, PA 18104-5708 Ph: (315) 857-5723 |
News Archive
A group of researchers from Australia and China recently demonstrated how SARS-CoV-2 spike glycoprotein subunit 1 can induce a pro-inflammatory signaling pathway (leading to cytokines deployment and epithelial damage in human bronchial epithelial cells), but also highlighted the potential of peptide-based antivirals in tackling this novel coronavirus.
Imagine babies so tiny a wedding ring can fit around their arms. Often weighing less than a pound, these remarkably small and sick infants hold onto life hooked up to a maze of tubes and beeping monitors.
Relypsa, Inc., a biopharmaceutical company developing non-absorbed polymeric drugs, today announced positive results from the company's PEARL-HF study, a Phase 2 clinical trial of the company's lead compound, RLY5016. These data were presented by Dr. Bertram Pitt, Professor of Medicine Emeritus, Division of Medicine at the University of Michigan School of Medicine, during the Late-Breaking Clinical Trials Session in an oral presentation titled "The PEARL-HF (Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple-Dose To Evaluate the Effects of RLY5016 in Heart Failure Patients) Trial" at the 14th Annual Scientific Meeting of the Heart Failure Society of America held in San Diego, CA September 13-15, 2010.
Transition Therapeutics Inc. today announced results from two phase 1 clinical studies of neuropsychiatric drug candidate ELND005. These studies, an absorption-metabolism-excretion ("AME") study and a renal clearance study, are specialized clinical pharmacology trials that are required by the United States Food and Drug Administration for the approval of most drugs in development.
› Verified 2 days ago
Adrienne Westheim, M.S, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 930 Springhouse Rd, Allentown, PA 18104 Phone: 610-390-5014 Fax: 610-398-7134 | |
Bailey Mckeon, M.A, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1925 W Turner St, Allentown, PA 18104 Phone: 610-794-5264 | |
Sarah Wanuga, MS, CCC-SLP/L Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 850 S 5th St, Allentown, PA 18103 Phone: 610-776-3578 | |
Megan Pellek, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 350 S Cedarbrook Rd, Allentown, PA 18104 Phone: 610-395-3727 Fax: 610-395-7919 | |
Cailee Carmella, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4136 W Tilghman St Apt 5, Allentown, PA 18104 Phone: 484-822-6040 | |
Ellen Susan Krajcir, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 850 S 5th St, Allentown, PA 18103 Phone: 610-776-3578 | |
Tiffany Ferreira, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1200 S Cedar Crest Blvd, Allentown, PA 18103 Phone: 888-402-5846 |